Mesoblast Limited (ASX:MSB)

Australia flag Australia · Delayed Price · Currency is AUD
2.400
-0.090 (-3.61%)
Sep 26, 2025, 4:10 PM AEST
-3.61%
Market Cap3.07B
Revenue (ttm)26.23M
Net Income (ttm)-155.80M
Shares Out1.28B
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,551,700
Average Volume5,098,189
Open2.430
Previous Close2.490
Day's Range2.360 - 2.450
52-Week Range1.020 - 3.370
Beta1.17
RSI54.44
Earnings DateNov 18, 2025

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 81
Stock Exchange Australian Securities Exchange
Ticker Symbol MSB
Full Company Profile

Financial Performance

In 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD Financial Statements

News

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic ce...

20 hours ago - GlobeNewsWire

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercia...

12 days ago - GlobeNewsWire

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into con...

23 days ago - GlobeNewsWire

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Conference Call August 28, 2025 6:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Of...

4 weeks ago - Seeking Alpha

Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Mesoblast Limited in conjunction with their 2025 Q4 earnings call.

4 weeks ago - Seeking Alpha

Full Year 2025 Mesoblast Ltd Earnings Presentation Transcript

Full Year 2025 Mesoblast Ltd Earnings Presentation Transcript

4 weeks ago - GuruFocus

Mesoblast (MESO) Sees Revenue Surge in FY25 with Ryoncil's FDA Approval

Mesoblast (MESO) Sees Revenue Surge in FY25 with Ryoncil's FDA Approval

4 weeks ago - GuruFocus

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Financial Results and Operational Update for the Full Year Ended June 30, 2025 Financial Results and Operational Update for the Full Year Ended June 30, 2025

4 weeks ago - GlobeNewsWire

Examining the Future: Mesoblast's Earnings Outlook

Mesoblast (NASDAQ: MESO) will release its quarterly earnings report on Thursday, 2025-08-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Mesoblast to report a...

4 weeks ago - Benzinga

Mesoblast shares soar 35pc on strong cell therapy sales data

The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.

2 months ago - The Australian Financial Review

Successful Commercial Launch of Ryoncil®

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sa...

2 months ago - Benzinga

Successful Commercial Launch of Ryoncil®

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales...

2 months ago - GlobeNewsWire

ASX 200 LIVE: ASX 200 at record; Mesoblast soars 30pc on sales boost

Shares trade strongly after BHP posts record year for iron ore and copper. Mesoblast reports strong sales in flagship. Atlas Arteria fails in 40 per cent toll hike bid. Follow live.

2 months ago - The Australian Financial Review

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday. Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Tuesday's session after the company announced align...

3 months ago - Benzinga

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

On Monday, Mesoblast Ltd . (NASDAQ: MESO) announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexleme...

3 months ago - Benzinga

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

On Monday, Mesoblast Ltd. MESO announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) f...

3 months ago - Benzinga

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States...

3 months ago - GlobeNewsWire

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum w...

3 months ago - GlobeNewsWire

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years ...

4 months ago - GlobeNewsWire

Mesoblast reports Q3 results

5 months ago - Seeking Alpha

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent...

5 months ago - GlobeNewsWire